(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 28 Apr 2016
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics
- Acronyms Vertex IIS
- 23 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 05 Aug 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.